JP7488774B2 - 化合物 - Google Patents

化合物 Download PDF

Info

Publication number
JP7488774B2
JP7488774B2 JP2020571762A JP2020571762A JP7488774B2 JP 7488774 B2 JP7488774 B2 JP 7488774B2 JP 2020571762 A JP2020571762 A JP 2020571762A JP 2020571762 A JP2020571762 A JP 2020571762A JP 7488774 B2 JP7488774 B2 JP 7488774B2
Authority
JP
Japan
Prior art keywords
compound
compounds
formula
group
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020571762A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021528449A5 (https=
JP2021528449A (ja
Inventor
ブラウン，パメラ
ドーソン，マイケル
シモノビック，モナ
ボークス，スティーブン
デュパーチー，エスター
リバース，ディーン
レスター，ロイ
コールマン，スコット
Original Assignee
スペロ・セラピューティクス・インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by スペロ・セラピューティクス・インコーポレーテッド filed Critical スペロ・セラピューティクス・インコーポレーテッド
Publication of JP2021528449A publication Critical patent/JP2021528449A/ja
Publication of JP2021528449A5 publication Critical patent/JP2021528449A5/ja
Priority to JP2024077064A priority Critical patent/JP2024109664A/ja
Application granted granted Critical
Publication of JP7488774B2 publication Critical patent/JP7488774B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/60—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation occurring through the 4-amino group of 2,4-diamino-butanoic acid
    • C07K7/62—Polymyxins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2020571762A 2018-06-25 2019-06-25 化合物 Active JP7488774B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024077064A JP2024109664A (ja) 2018-06-25 2024-05-10 化合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862689602P 2018-06-25 2018-06-25
US62/689,602 2018-06-25
PCT/EP2019/066819 WO2020002325A1 (en) 2018-06-25 2019-06-25 Compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024077064A Division JP2024109664A (ja) 2018-06-25 2024-05-10 化合物

Publications (3)

Publication Number Publication Date
JP2021528449A JP2021528449A (ja) 2021-10-21
JP2021528449A5 JP2021528449A5 (https=) 2022-07-07
JP7488774B2 true JP7488774B2 (ja) 2024-05-22

Family

ID=67107423

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020571762A Active JP7488774B2 (ja) 2018-06-25 2019-06-25 化合物
JP2024077064A Pending JP2024109664A (ja) 2018-06-25 2024-05-10 化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024077064A Pending JP2024109664A (ja) 2018-06-25 2024-05-10 化合物

Country Status (31)

Country Link
US (3) US11459357B2 (https=)
EP (2) EP3810633B1 (https=)
JP (2) JP7488774B2 (https=)
KR (1) KR20210054500A (https=)
CN (2) CN112789287B (https=)
AR (1) AR116663A1 (https=)
AU (2) AU2019294261B2 (https=)
BR (1) BR112020026663A2 (https=)
CA (1) CA3103158A1 (https=)
CO (1) CO2020016080A2 (https=)
DK (1) DK3810633T3 (https=)
EA (1) EA202092819A1 (https=)
ES (1) ES2971732T3 (https=)
FI (1) FI3810633T3 (https=)
HR (1) HRP20240028T1 (https=)
HU (1) HUE065134T2 (https=)
IL (2) IL279620B2 (https=)
LT (1) LT3810633T (https=)
MA (1) MA52946B1 (https=)
MD (1) MD3810633T2 (https=)
MX (1) MX2020013811A (https=)
PH (1) PH12020552240A1 (https=)
PL (1) PL3810633T3 (https=)
PT (1) PT3810633T (https=)
RS (1) RS65128B1 (https=)
SG (1) SG11202012747VA (https=)
SI (1) SI3810633T1 (https=)
TW (2) TW202446783A (https=)
UA (1) UA128162C2 (https=)
WO (1) WO2020002325A1 (https=)
ZA (1) ZA202301937B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024109664A (ja) * 2018-06-25 2024-08-14 スペロ・セラピューティクス・インコーポレーテッド 化合物

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107108699A (zh) 2014-11-26 2017-08-29 新药物许可控股有限公司 化合物
TW202233649A (zh) 2020-11-06 2022-09-01 美商斯佩羅治療學股份有限公司 化合物
WO2022262823A1 (zh) * 2021-06-18 2022-12-22 华南理工大学 活性氧自由基响应的多粘菌素前药化合物及其应用
CN120574287A (zh) * 2025-06-10 2025-09-02 中国药科大学 一种抗菌肽、组合物及应用
CN120518715B (zh) * 2025-07-24 2025-10-03 中国药科大学 一种抗菌肽、药物组合物及应用
CN120699105B (zh) * 2025-08-19 2025-11-21 中国药科大学 一种氘代抗菌肽及其组合物和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012168820A1 (en) 2011-06-08 2012-12-13 Pfizer Inc. Polymyxin derivatives useful as antibacterial agents
JP2014533678A (ja) 2011-11-18 2014-12-15 ノヴァクタ バイオシステムズ リミティッド ポリミキシン誘導体
JP2017510570A (ja) 2014-03-11 2017-04-13 ニュー・ファーマ・ライセンス・ホールディングス・リミテッド 異なった抗生物質と一緒の組合せ療法におけるポリミキシン誘導体及びその使用
JP2017538692A (ja) 2014-11-26 2017-12-28 ニュー・ファーマ・ライセンス・ホールディングス・リミテッド 化合物

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2128617A (en) 1982-10-06 1984-05-02 Martti Vaara Polypeptides for use in antibacterial therapy
WO1988000950A2 (fr) 1986-08-06 1988-02-11 Fauchere Jean Luc Fabrication de conjugues a liaisons de covalence a partir d'un antibiotique et d'un derive non toxique de la polymyxine b
US20010021697A1 (en) 1987-09-14 2001-09-13 Henning Lowenstein Methods and compositions for the treatment of mammalian infections employing medicaments comprising hymenoptera venom, proteinageous or polypeptide components thereof, or analogues of such proteinaceous or polypeptide components
TW274552B (https=) 1992-05-26 1996-04-21 Hoechst Ag
US5767068A (en) 1997-02-13 1998-06-16 Pathogenesis Corporation Pure biologically active colistin, its components and a colistin formulation for treatment of pulmonary infections
AU2004277977B2 (en) 2003-09-30 2010-10-28 Biomechanisms Inc. Compositions and methods for treating burns
US20060004185A1 (en) 2004-07-01 2006-01-05 Leese Richard A Peptide antibiotics and peptide intermediates for their prepartion
US7807637B2 (en) 2006-08-11 2010-10-05 Northern Antibiotics Oy Polymyxin derivatives and uses thereof
HUE028271T2 (en) 2006-08-11 2016-12-28 Northern Antibiotics Oy Polymixin derivatives and their applications
FI20085469A0 (fi) 2008-02-08 2008-05-16 Northern Antibiotics Oy Polymyksiinijohdannaiset, joissa on lyhyt rasvahappohäntä, ja niiden käyttöjä
US8193148B2 (en) 2008-02-08 2012-06-05 Northern Antibiotics Ltd. Short fatty acid tail polymyxin derivatives and uses thereof
US8329645B2 (en) 2008-02-08 2012-12-11 Northern Antibiotics Ltd. Polymyxin derivatives and uses thereof
ES2334547B1 (es) 2008-09-10 2010-12-03 Universidad De Barcelona Compuestos peptidicos antibacterianos.
TW201035111A (en) 2008-12-23 2010-10-01 Biosource Pharm Inc Antibiotic compositions for the treatment of gram negative infections
CN101851270A (zh) 2009-04-03 2010-10-06 梁浩 一种多粘菌素衍生物及其制备方法
WO2010130007A1 (en) 2009-05-14 2010-11-18 Monash University Antimicrobial compounds
US8415307B1 (en) 2010-06-23 2013-04-09 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections
WO2012051663A1 (en) 2010-10-21 2012-04-26 Monash University Antimicrobial compounds
JP6643758B2 (ja) 2013-05-22 2020-02-12 スペロ・セラピューティクス・インコーポレーテッド 異なった抗生物質と一緒の組合せ療法におけるポリミキシン誘導体及びその使用
US10047126B2 (en) 2014-04-01 2018-08-14 Monash University Polymyxin derivatives as antimicrobial compounds
KR20170098821A (ko) * 2014-12-17 2017-08-30 에프. 호프만-라 로슈 아게 소르타아제를 사용한 １ 단계로의 이중 폴리펩티드 컨쥬게이션을 위한 효소 원-포트 반응
WO2016166103A1 (en) * 2015-04-13 2016-10-20 Xellia Pharmaceuticals Aps Polymyxin derivatives
EP3356387B1 (en) * 2015-09-29 2024-06-26 Monash University Antimicrobial polymyxin derivative compounds
AU2017285424B2 (en) * 2016-06-16 2022-08-18 International Aids Vaccine Initiative, Inc. Tuberculosis compositions and methods of treating or preventing tuberculosis
MD3810633T2 (ro) * 2018-06-25 2024-05-31 Spero Therapeutics Inc Compuşi
WO2020014501A1 (en) 2018-07-11 2020-01-16 Cidara Therapeutics, Inc. Compositions and methods for the treatment of bacterial infections

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012168820A1 (en) 2011-06-08 2012-12-13 Pfizer Inc. Polymyxin derivatives useful as antibacterial agents
JP2014533678A (ja) 2011-11-18 2014-12-15 ノヴァクタ バイオシステムズ リミティッド ポリミキシン誘導体
JP2017510570A (ja) 2014-03-11 2017-04-13 ニュー・ファーマ・ライセンス・ホールディングス・リミテッド 異なった抗生物質と一緒の組合せ療法におけるポリミキシン誘導体及びその使用
JP2017538692A (ja) 2014-11-26 2017-12-28 ニュー・ファーマ・ライセンス・ホールディングス・リミテッド 化合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Journal of Medicinal Chemistry，2013年，Vol.56，p.5079-5093

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024109664A (ja) * 2018-06-25 2024-08-14 スペロ・セラピューティクス・インコーポレーテッド 化合物

Also Published As

Publication number Publication date
EP3810633A1 (en) 2021-04-28
AR116663A1 (es) 2021-06-02
LT3810633T (lt) 2024-01-10
CN112789287B (zh) 2024-06-21
IL279620B2 (en) 2026-03-01
UA128162C2 (uk) 2024-04-24
WO2020002325A1 (en) 2020-01-02
AU2024203362A1 (en) 2024-06-06
SG11202012747VA (en) 2021-01-28
CN118878638A (zh) 2024-11-01
HUE065134T2 (hu) 2024-05-28
MX2020013811A (es) 2021-03-09
HRP20240028T1 (hr) 2024-03-29
EP3810633B1 (en) 2023-12-13
US20260103491A1 (en) 2026-04-16
DK3810633T3 (da) 2024-01-15
IL279620B1 (en) 2025-11-01
IL279620A (en) 2021-03-01
TW202446783A (zh) 2024-12-01
FI3810633T3 (fi) 2024-02-09
CA3103158A1 (en) 2020-01-02
JP2021528449A (ja) 2021-10-21
MA52946B1 (fr) 2024-03-29
AU2019294261B2 (en) 2024-02-29
AU2019294261A1 (en) 2021-02-04
IL323560A (en) 2025-11-01
ES2971732T3 (es) 2024-06-06
NZ771833A (en) 2024-09-27
ZA202301937B (en) 2023-09-27
RS65128B1 (sr) 2024-02-29
PT3810633T (pt) 2024-02-19
CN112789287A (zh) 2021-05-11
US11459357B2 (en) 2022-10-04
US20210246169A1 (en) 2021-08-12
US12528837B2 (en) 2026-01-20
TW202019949A (zh) 2020-06-01
PL3810633T3 (pl) 2024-04-08
MA52946A (fr) 2021-04-28
EP4316504A3 (en) 2024-04-17
CO2020016080A2 (es) 2021-01-18
PH12020552240A1 (en) 2021-08-16
SI3810633T1 (sl) 2024-04-30
EA202092819A1 (ru) 2021-05-21
EP4316504A2 (en) 2024-02-07
JP2024109664A (ja) 2024-08-14
KR20210054500A (ko) 2021-05-13
TWI851584B (zh) 2024-08-11
BR112020026663A2 (pt) 2021-03-23
MD3810633T2 (ro) 2024-05-31
US20230012121A1 (en) 2023-01-12

Similar Documents

Publication Publication Date Title
JP7488774B2 (ja) 化合物
JP6643758B2 (ja) 異なった抗生物質と一緒の組合せ療法におけるポリミキシン誘導体及びその使用
RU2740190C2 (ru) Производные полимиксина и их применение в комбинированной терапии совместно с различными антибиотиками
CN103946233A (zh) 多黏菌素衍生物
JP7349773B2 (ja) 化合物
HK40098322A (en) Compounds
EA047835B1 (ru) Соединения
HK40040020B (en) Compounds
HK40040020A (en) Compounds
TW202233649A (zh) 化合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220627

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220627

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220629

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230517

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230519

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230821

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231024

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240124

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240412

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240510

R150 Certificate of patent or registration of utility model

Ref document number: 7488774

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150